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Background: The objective of this study was to determine the gene expression profiles of the androgen/androgen
receptor (AR) and anti-Müllerian hormone (AMH)/ Sry-related high-mobility group box 9 (SOX9) pathways in
granulosa-luteal cells from patients undergoing standard in vitro fertilization (IVF) with or without recombinant
luteinizing hormone (rLH) therapy.
Methods: Levels of reproductive hormones in the pre-ovulatory follicular fluid and the expression levels of LHR
(luteinizing hormone receptor), AR, SOX9, AMH, AR-associated protein 54(ARA54)and ARA70 were determined in
granulosa-luteal cells by real-time reverse-transcription PCR. The effects of androgen and rLH treatments on AR and
AMH expression levels were also tested in vitro using HO23 cells.
Results: We collected 35 an 70 granulosa cell samples from patients cycled with and without rLH supplementation,
respectively. The clinical outcomes were similar in patients who received rLH therapy and those who did not,
though the pre-ovulatory follicular fluid levels of androstenedione, testosterone, and estradiol were significantly
higher and progesterone was lower in the rLH supplementation group. Moreover, granulosa-luteal cell mRNA levels
of LHR, AR, AMH, and SOX9 were significantly higher in the rLH supplementation group relative to the group that
did not receive rLH supplementation. In addition, we observed significant correlations between LHR and AR mRNA
expression and among AR, AMH, and SOX9 mRNA expression in granulosa-luteal cells from patients undergoing
standard IVF treatment.
Conclusions: Increased expression of LHR, AR, AMH, and SOX9 is characteristic of granulosa-luteal cells from IVF/
intracytoplasmic sperm injection (ICSI) patients receiving rLH supplementation.
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Controlled ovarian hyperstimulation (COH) is one of
the pivotal steps in assisted reproductive technology
(ART). The role of endogenous luteinizing hormone
(LH) levels and the effect of LH on follicular maturation
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reproduction in any medium, provided the orattracted a great deal of attention since the early years of
in vitro fertilization (IVF) [1,2]. With the availability of
recombinant human LH (rLH), clinicians now have the
opportunity to administer two gonadotropins independ-
ently. Thus, exogenous rLH administration can be calibrated
independently of recombinant follicle-stimulating hormone
(rFSH).
The use of rLH for COH with respect to indications,
timing, and dosage has not been fully elucidated [3,4]. A
growing body of evidence seems to indicate a beneficial
effect of co-treatment with rFSH and rLH, in particular
for patients suffering pregnancy loss, poor responders. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Lan et al. Reproductive Biology and Endocrinology 2013, 11:11 Page 2 of 11
http://www.rbej.com/content/11/1/11[5-8] and patients of advanced age who undergo ART
[6,9-13]. However, because of the relatively small sample
sizes, many of these trials were underpowered for evalu-
ating clinical pregnancy as a primary outcome and were
thus inconclusive as to the benefit of rLH therapy. To
better establish the role of LH in IVF, additional basic
research and randomized, focused clinical trials are
needed [9,14,15].
Ovarian androgens are produced by thecal cells and
exert their action in a paracrine fashion on granulosa
cells. Androgen action is mediated by the androgen
receptor (AR), which, like other members of the steroid
receptor superfamily, interacts directly with target genes
to regulate transcription [16]. Several coactivator proteins
have been shown to bind steroid receptors and enhance
their interaction with basal transcription factors, thereby
amplifying the transcriptional activation potential of the
receptor. Among these coactivators are the AR-associated
protein 54 (ARA54) and ARA70 [17]. We previously
proposed the possibility of a transition in androgen action
from an enhancer of follicular differentiation (through
the AR) to a substrate for estrogen synthesis (through
aromatase) at the time of oocyte retrieval [17].
Sry-related high-mobility group box (SOX) proteins
make up a large family of transcription factors that share
a homologous high-mobility group (HMG) DNA-binding
domain and are key regulators of many developmental
and tissue-specific processes. In the developing gonad,
SOX9 plays a critical role in male sex determination by
stimulating the expression of anti-Müllerian hormone
(AMH) [18]. Recent clinical evidence showed that serum
AMH levels might be a sensitive predictive parameter of
ovarian status [19]. Evidence indicates a negative role for
AMH of pre-granulosa/granulosa cell origin in this key
event and subsequent progression to the antral stage
[20]. Whether intrafollicular AMH is involved in the
autocrine/paracrine regulation of granulosa and theca
cell function in pre-ovulatory antral follicles remains un-
clear. Notably, the poor responders who benefit from co-
treatment with rFSH and rLH [3,5-8] usually also exhibit
extremely low serum AMH levels [19]. The “two-cell
-two-gonadotropin” theory posits that ovarian theca cells
stimulated by LH produce androgens, which are then
converted by granulosa cells into estrogens under FSH
stimulation [21]. However, the action of LH on follicular
development is unlikely to be limited to providing an an-
drogen substrate for aromatization. In fact, LH also dir-
ect stimulates and modulates folliculogenesis [22].
However, the efficacy of rLH in the follicular fluid micro-
environment and on luteinized granulosa cells has been
less thoroughly assessed, and studies focusing on the
interaction between LH, androgen/AR and AMH/SOX9
in granulosa cells are limited [23-27]. Our aim in this
study was to examine whether rLH therapy affects thegene expression profiles of the androgen/AR or AMH/
SOX9 endocrine and paracrine hormonal signaling
pathways in human luteinized granulosa cells.
We measured the expression levels of the luteinizing
hormone receptor (LHR), AR, AR coactivators, SOX9,
and AMH in granulosa cells collected from IVF/ICSI
patients on the gonadotropin-releasing hormone agonist
(GnRHa) protocol for ovarian stimulation, with or with-
out rLH co-treatment with rFSH. In addition, we treated
the human granulosa cell line HO-23 with rLH or
androgen in vitro to investigate whether the gene ex-
pression profiles of the AR and AMH pathways were
regulated by both LH and androgen.
Methods
COH Protocol
539 Patients undergoing their first ART treatment with
a long COH protocol were enrolled in the study. This
study was approved by the Ethics Committee of Chang
Gung Memorial Hospital. Approval from the institu-
tional review board was obtained for the analysis of this
series (CGMH94-360). The study included patients who
underwent IVF/intracytoplasmic sperm injection in our
institution between March 1, 2004 and September 30,
2006. Within this study period, 35 patients received rLH
supplementation cycles (12 patients with antral follicle
count (AFC) <6; 2 patients with previous intrauterine
insemination (IUI) poor response history; 7 patients with
age > 35 years old; 10 patients with mid-follicular serum
estradiol <100 pg/mL or LH < 0.5mIU/mL; 2 patients
with poor follicular growth rate in the mid-follicular
phase; 1 patient with deep infiltrating endometriosis his-
tory and 1 patient due to obesity). To match appropriate
candidates to compare outcome efficiency, a 2:1 individ-
ual matching case-control design [28] was used to recruit
70 patients who did not receive rLH supplementation
cycles but matched the demographic characteristics of
the 35 patients receiving rLH therapy (Figure1). At that
time, it has been suggested that recombinant LH can be
used in a group of unselected IVF patients [29]. All
patients provided informed consent for their participa-
tion in the molecular investigation. The COH procedure
was followed by the standard down-regulation protocol,
as published previously [30]. Briefly, GnRHa (Lupron;
Abbott Australasia PTY, Ltd., Kurnell, New South Wales,
Australia) was administered from the mid-luteal phase,
and rFSH (Gonal-F; Serono Laboratories, Aubonne,
Switzerland) was administered after pituitary desensitization
was achieved. Patients received one of the following fixed
starting doses (age < 35: 225 IU/day; age≥35: 300 IU/day) of
rFSH (Gonal-F, 75 IU/ampoule, Serono Laboratories,
Aubonne, Switzerland) after pituitary suppression with
GnRHa. Gonadotropin was administered daily for 5 days,
after which the dose was individualized according to
569 standard down-regulation long protocol cycles with
granulosa cells obtained from 569 patients
534 non-add LH cycles
in 534 patients
70 non-add LH cycles
in 70 patients
35 add LH cycles in 35 patients
Add LH criteria:
1. (n=12)
2. Previous poor IUI response (n=2)
3. Age 35 (n=7)
4. E2 < 100 pg/mL or LH < 0.5 mIU/mL
in the mid-follicular phase (n=10)
5. Poor follicular growth rate in the mid-
follicular phase (n=2)
6. DIE History (n=1)
7. Obesity (n=1)
Figure 1 Flow diagram of 539 patients who attended the case-control study.
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Monitoring of transvaginal ultrasound and serum estradiol
(E2) was performed every 2 to 3 days starting on the
5th day of stimulation. After 6 days of rFSH stimulation,
patients who had ever received co-treatment with 75 IU
of rLH (Luveris; Merck Serono SA, Aubonne Branch,
Switzerland) were submitted to the rLH supplementation
group. rFSH, with or without rLH, was continuously
administered until 2 of the dominant follicles reached
18 mm, and then the patients received 250 μg of hCG
(Ovidrel; Merck Serono, Inc., West Orange, NJ, USA).
Collection of primary human granulosa cells
Thirty-four to 36 hours after hCG administration, fol-
licular fluid (FF) and luteinized granulosa cells were
collected by means of transvaginal ultrasound-guided
oocyte retrieval. A double-lumen needle was used for
aspiration because the puncture needle used to obtain a
sample of uncontaminated luteinized granulosa cells was
not withdrawn before entering the next follicle. Only the
first aspirate of pre-ovulatory follicles without bloodcontamination from one ovary was used for this study.
After follicular aspiration, the cumulus-oocyte complexes
were separated for IVF, and the luteinized granulosa cells
were flushed with IVF medium to disperse the cells. The
cells were then immediately transported to the labora-
tory. The follicular fluid was stored under the same
conditions as serum. The FF samples were analyzed for
testosterone, estradiol, progesterone, and androstene-
dione. The dispersed cells were transferred to a 15-mL
centrifuge tube containing 4 mL of Histopaque 1077
(Sigma Chemical Co., St. Louis, MO, USA). Human
luteinized granulosa cells were separated from red blood
cells by centrifugation at 600 × g for 10 minutes. Granulosa
cells formed a thin layer between the Histopaque and the
medium [31] and were collected as previously reported [17].
Cell lines and culture conditions
The HO23 human immortalized luteinized granulosa
cell line, provided by Dr. Abraham Amsterdam,
Weizmann Institute of Science, Rehovot, Israel [32], was
used for in vitro analyses. HO23 cells were established
Table 1 Oligonucleotide primer sequences for LHR, AR,
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and a temperature-sensitive (ts) mutant of the p53 tumor
suppressor gene (p53val135) in primary granulosa cells
obtained from IVF patients. The cells were maintained at
37°C and 5% CO2 in Dulbecco’s minimal essential medium
(DMEM)/Ham’s F12 (1:1), supplemented with 5% fetal
calf serum and antibiotics (100 IU/mL penicillin and
100 mg/mL streptomycin). To test the effect of rLH or an-
drogen on AR and AMH expression, cells (5 × 105) were
seeded on 100-mm culture dishes and incubated for 24
hours. The media were then removed, and the cells were
reincubated in medium supplemented with charcoal-
dextran-treated serum and then treated with different
concentrations of DHT or rLH for 24 hours.
RNA extraction
Total RNA was extracted from granulosa cells (5 × 105)
using TRIzol reagent (Gibco-BRL, Grand Island, NY,
USA). Briefly, 1 mL of TRIzol was added to the
granulosa cells. The mixture was pipetted and allowed
to sit for 5 minutes at room temperature. Chloroform
(0.2 mL) was added, mixed, and allowed to incubate at
room temperature for 3 minutes. The mixture was then
processed by centrifugation at 12,000 × g for 15 minutes,
and the supernatant was transferred to a fresh tube. Iso-
propanol (0.5 mL) was added, mixed, and incubated
for 10 minutes at room temperature. The solution
was then processed by centrifugation at 12,000 × g for
10 minutes, and the RNA was purified.. The pellet was
washed once with 70% ethanol, resuspended in H2O,
and stored at -80°C. The concentrations of the RNA
samples were determined by measuring the absorbance
at 260 nm in a spectrophotometer (DUW 640B, Beckman
Coulter, USA).
cDNA synthesis
Two micrograms of total RNA from the sample prepar-
ation were reverse-transcribed in 25 μL as follows: 0.1
μg of random hexamer primers (Amersham Pharmacia
Biotech, Inc., Buckinghamshire, UK) were denatured for
10 minutes at 70°C in a Gradient Cycler (DNA Engine,
Watertown, MA, USA), and then the reverse transcrip-
tion reaction was performed at 42°C for 1 hour by
adding 5× reverse transcriptase buffer (500 mM of each
dNTP, 3 mM MgCl2, 75 mM KCl, and 50 mM Tris-HCl
[pH 8.3]), 1 mM dNTP (Promega, Madison, WI, USA),
10 IU RNase inhibitor (Promega), and 100 U MMLV
reverse transcriptase (Promega). The reverse transcriptase
was inactivated by heating at 95°C for 5 minutes and
cooling at 4°C for 5 minutes.
Quantitative RT-PCR
Specific PCR amplification products were detected using
an ABI PRISM 7700 sequence detector system (Perkin-Elmer Applied Biosystems, Los Angeles, CA, USA) and
the SYBR green PCR master mix kit (Applied Biosystems,
Foster City, USA), according to the manufacturer’s
protocol. The forward and reverse primer sequences for
AR, AR co-factors, SOX9, AMH, LHR and ß-actin and
18S are listed in Table 1. Duplicate experiments were
performed for each set of experimental conditions, and
we retested any sample with a > 1% coefficient of vari-
ation for the Ct value. Quantitative values are obtained
from the threshold cycle (Ct) number at which the in-
crease in signal associated with an exponential growth of
PCR product starts to be detected (using 7500 Fast Sys-
tem SDS software (Applied Biosystems)), according to
the manufacturer’s manual. The precise amount of total
RNA added to each reaction (based on absorbance) and its
quality (i.e., lack of extensive degradation) are both difficult
to assess. We quantified ß-actin or 18S gene transcripts as
an endogenous RNA control, and normalized each sample
with respect to its ß-actin or 18S content. Final results, ex-
press as N-fold differences in target gene expression relative
to the β-actin gene termed “N target,” are determined as
follows: N target=2△Ct samplewhere the △Ct values of the
sample were determined by subtracting the average Ct
value of the target gene from the average Ct value of the
ß-actin or 18S gene in each sample.
Statistical analysis
Data analyses were performed with SPSS 10.0 software
(Statistical Package for Social Sciences, Inc., Chicago, IL,
USA). Continuous data were summarized as the mean ±
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correlations in gene expression were examined. A mul-
tiple regression analysis with the stepwise forward pro-
cedure (multivariate analysis) was used to identify
independent factors and to test for interactions between
the covariates. The clinical outcome comparison used
the Mann-Whitney rank-sum test for the comparison
of means and the Fisher’s exact test for proportions. All
P values were two-sided, and P < 0.05 was considered
statistically significant.Results
The study population comprised two groups of patients.
One group (35 patients) received rLH supplementation
cycles during the IVF procedure, while the control group
(70 patients) did not. The two groups were comparable
in terms of age, BMI, mean duration of infertility, indica-
tion for treatment, days of FSH treatment, endometrial
thickness, estradiol and progesterone levels on the day
of hCG administration, and the number of oocytes and
mature oocytes retrieved (Table 2).Table 2 Comparison of patients treated with Add-rLH or Non
Transfer Add-r
No. patients
Age of female partners (yrs) 33.4









Duration of infertility (years) 4.0
Days of FSH treatment 8.6
FSH (IU) 2062.5
LH (IU) 3525.0
Endometrial thickness on day of hCG stimulation (cm) 1.4
LH (mIU/mL) on day of hCG stimulation 2.6
Estradiol (pg/mL) on day of hCG stimulation 1681.9
Progesterone (ng/mL) on day of hCG stimulation 1.2
No. mature & near-mature oocytes retrieved 5.9
No. mature oocytes retrieved 3.7
Normal fertilization rate 77.8 +
Mean No. embryos transferred 2.1
Clinical pregnancy rate per transfer 34.2%
Note: Values are mean ± SD or proportion.We found that the fertilization rate, mean number of
embryos transferred, and clinical pregnancy rate per
transfer were similar between the two groups. The
serum LH level on the day of hCG administration was
the only parameter to show a statistically significant
difference between the two groups (2.6 +/- 1.6 mIU/mL
vs. 1.9 +/- 1.2 mIU/mL, P =0.021; Table 2). However, the
concentrations of androstenedione, testosterone, estradiol
and progesterone in the pre-ovulatory dominant follicular
fluid were significantly different between groups. Follicular
fluid levels of androstenedione (76.4+/- 43.2 vs. 54.1+/-
42.6), testosterone (10.1+/- 3.5 vs. 9.4 +/- 6.0), and estradiol
(336619.8 +/- 366528.9 vs.195014.7 +/- 257784.7) were
higher, and progesterone was lower (10337.9 +/- 5138.1
vs. 11974.4 +/- 20806.6) in the rLH supplementation groups
(Table 3).
We next examined whether the expression levels of po-
tential genes involved in the androgen and AMH pathways
were influenced by rLH supplementation during COH.
The mRNA levels of the LH receptor (LHR), AR, SOX9,
AMH, ARA54 and ARA70 were quantified by real-time
RT-PCR in luteinized granulosa cell samples obtained-Add-rLH IVF down-regulation regimens
LH cycles Non-Add-rLH cycles P
35 70
+/- 4.1 33.2 +/- 4.2 ns
+/- 3.1 21.6 +/- 3.1 ns
(24/35) 55.7 (39/70) ns





+/- 2.4 4.0 +/- 3.0 ns
+/- 1.8 9.1 +/- 1.7 ns
+/- 975.0 2385.0 +/- 855.0 ns
+/- 225.0
+/- 0.3 1.3 +/- 0.3 ns
+/- 1.6 1.9 +/- 1.2 0.021
+/- 1021.7 1851.8 +/- 1166.2 ns
+/- 0.4 1.1 +/- 0.4 ns
+/- 4.2 6.5 +/- 3.3 ns
+/- 2.7 3.9 +/- 2.1 ns
/- 33.1% 79.4 +/- 23.3% ns
+/- 0.6 2.3 +/- 0.6 ns
(12/35) 32.8% (23/70) ns
Table 3 Comparison of follicular fluid concentrations at oocyte retrieval in patients treated with Add-LH or Non-Add
rLH IVF down-regulation regimens
Transfer Add-rLH cycles Non-Add rLH cycles P
No. patients 35 70
Androstenedione (ng/mL) 76.4+/- 43.2 54.1+/- 42.6 0.009
Testosterone (ng/mL) 10.1+/- 3.5 9.4 +/- 6.0 0.021
Estradiol (pg/mL) 336619.8 +/- 366528.9 195014.7+/- 257784.7 0.034
Progesterone (ng/mL) 10337.9 +/- 5138.1 11974.4+/-20806.6 0.007
Note: Measurements were taken on the day of oocyte retrieval. Values are mean ± SD.
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rLH supplementation (70 patients). The results are
summarized in Figure 2 and Additional file 1: Figure S1.
Of note, the expression of LHR, AR, SOX9, and AMH was
significantly higher in granulosa cells obtained from
women who received rLH supplementation. AR co-
regulators, i.e., ARA70 and ARA54, were expressed at simi-
lar levels between groups. Linear regression revealed that
AMH, SOX9 and AR expression levels in granulosa cells
were positively correlated (Figure 3, Figure 4 and Table 4).
ARA54 and ARA70 expression levels were significantly
correlated with SOX9 and AMH, respectively (Table 4).
There was also a positive correlation between LHR and AR
expression (Figure 3 and Table 4).
To investigate whether androgen or rLH treatment
can regulate AR or AMH expression levels in vitro, the
human granulosa cell line HO23 was treated with increas-
ing doses of DHT (0, 1 x 10-9 M, 1 x 10-8 M, 1 x 10-7 M, or
1 x 10-6M) or rLH (0, 0.5 IU/mL, 1 IU/mL, 1.5 IU/mL, or
2 IU/mL). Total RNA was collected 24 hours after treat-
ment, and AR and AMH mRNA levels were measured by
quantitative RT-PCR. We observed that increasing the dose
of DHT tended to increase AR but decrease AMH expres-
sion in HO23 cells. In addition, increases in AR and AMHFigure 2 Quantitative analysis of LHR, AR, AMH, SOX9, ARA54
and ARA70 mRNA levels in granulosa-luteal cells collected at
oocyte retrieval. Each bar represents the mean ± SD. Concomitant
detection of β-actin mRNA in the real-time RT-PCR reaction served
as a reference for relative quantification. * P < 0.05.mRNA expression were observed with increasing doses of
rLH (Figure 5 and Additional file 2: Figure S2).Discussion
In the present work, we demonstrate that human
granulosa-luteal cells supplemented with rLH exhibit
increased expression of LHR, AR, SOX9, and AMH. This
report is the first study to compare the expression
profiles of genes in the androgen receptor and anti-
Müllerian hormone in pre-ovulatory granulosa cells from
IVF/ICSI patients receiving rLH supplementation for
COH. Patients with low expression of AR, AMH, and
SOX9 may require a different follow-up schedule and
corresponding rLH treatment.
Little is known about the extremely complex process that
generates a developmentally competent oocyte. During
folliculogenesis and oogenesis, the oocyte is surrounded
by granulosa cells. The two cell types communicate
bidirectionally through secretion of steroid hormones and
paracrine factors. This communication plays a key role in
folliculogenesis and is essential for an oocyte to achieve
fertilization and undergo embryogenesis [33].
It has been suggested that the expression levels of
hormonally-regulated genes in granulosa cells can be
used as markers for oocyte quality and hence develop-
mental potential [34,35]. This development is mirrored
by the FSH-induced increase in estradiol biosynthesis in
granulosa cells after adequate stimulation of theca cells
by LH [36]. In 2004, Westergaard et al. found that the
follicular fluid concentrations of LH, estradiol and andro-
stenedione were significantly higher and progesterone
levels were significantly lower in women treated with go-
nadotropin plus rLH relative to women treated with re-
combinant rFSH alone [37]. Smitz et al. also reported
that major differences in the serum and follicular fluid
endocrine profiles exist after stimulation with gonado-
tropin and LH, as exogenous LH activity may induce a
different endocrine environment [38]. In agreement with
these reports [37,38], we found that the addition of rLH
was associated with increased estradiol, testosterone, and
androstenedione and reduced progesterone in the fluid
of the dominant follicle.
Figure 3 Linear regression revealed positive correlations in gene expression patterns. (A) AMH and SOX9 expression; (B) AMH and AR
expression; (C) SOX9 and AR expression; and (D) LHR and AR expression.
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ive age, and the levels vary.
Slightly with the menstrual cycle, reaching a peak value
in the late follicular phase. AMH expression follows a
similar pattern in humans compared with mice and rats,
suggesting an important role for AMH in folliculogenesis
[39]. Wunder et al. [40] reported that serum and follicu-
lar fluid AMH levels on the day of oocyte retrieval are
correlated with reproductive outcome. From molecular
point of view, AMH has been shown to be a downstream
target of SOX9. Upregulation of SOX9 can promote the
expression of AMH [18]. While increased intrafollicular
androgen levels have been associated with significant
increases in granulosa cell production of AMH [41], few
studies have investigated how reproductive hormones
such as LH influence the interaction between the andro-
gen/AR and AMH/SOX9 pathways in granulosa cells.
We demonstrated that luteinized granulosa cells from
IVF patients supplemented with rLH display increased
LHR, AR, SOX9, and AMH expression and highertestosterone and androstenedione concentrations in the
follicular fluid. Androgens are considered detrimental to
the late stages of folliculogenesis [42], and hyperandrogenic
polycystic ovary syndrome (PCOS) is associated with fol-
licular development arrest and poor oocyte quality [43]. It
is possible that LH may stimulate ovarian theca cells to
produce androgens that act cooperatively with LH in a
paracrine fashion on granulosa cells. Our in vitro model
showed that DHT alone can downregulate AMH expres-
sion, but increased expression of AR and AMH was
observed after rLH treatment. Indeed, many factors [44,45]
other than androgens may have affected the expression of
AR, AMH and SOX9 under rLH treatment. Increased es-
tradiol or decreased progesterone in the follicular fluid may
also influence LH-regulated granulosa cell gene expression.
Further studies on interaction between LH and sex steroid
hormones will be of interest.
The homogeneity of our study population is an advan-
tage because it reduces the possibility of confounding
population substructures or admixtures. However, because
Figure 4 Linear regression revealed positive correlations in gene expression patterns in LH (A-C) and non-add LH (D-F) groups.
(A) SOX9 and AR expression; (B) AMH and AR expression; (C) AMH and SOX9expression (D) SOX9 and AR expression; (E) AMH and AR expression;
(F) AMH and SOX9expression.
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Table 4 Linear regression analysis of LHR, AR, AMH,
SOX9, ARA54 and ARA70 mRNA expression in
granulosa-luteal cells collected at oocyte retrieval
Comparison variable B 95.0% Confidence interval for B P
LHR






AMH 0.326 0.160; 0.492 <0.001
SOX9 0.514 0.262; 0.766 <0.001




AR 0.299 0.168; 0.429 <0.001
AMH 0.227 0.105; 0.348 <0.001
LHR ns
ARA70 ns
ARA54 0.218 0.094; 0.341 0.001
AMH
AR 0.370 0.153; 0.587 0.001
SOX9 0.517 0.227; 0.807 0.001
LHR ns





LHR 0.388 0.062; 0.715 0.020








Figure 5 The effects of rLH and DHT on AR and AMH
expression. (A) AR and (B) AMH expression levels were measured in
HO-23 human granulosa cells under serum-free conditions in the
presence of DHT or rLH at the indicated concentrations for 24 hours.
Data are expressed as the mean +/- standard deviation (SD) of three
different experiments. * P < 0.05 vs. ethanol treatment; DHT,
dihydrotestosterone; rLH, luteinizing hormone.
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patients, the results may not be generalizable to
other ethnicities. Although our study showed no sig-
nificant differences in terms of clinical outcomes
with or without rLH supplementation (Table 2), the
study was underpowered to look at pregnancy ratesbetween the two groups. Our experiments did demon-
strate that granulosa-luteal cells supplemented with
rLH displayed increased expression of LHR, AR,
SOX9, and AMH. As it is difficult to extrapolate the
role of rLH in follicular growth and oocyte maturation
based on our results, further molecular and cellular
functional studies are required to investigate whether
rLH therapy has unremarkable benefits or perhaps an
undetermined effect on follicular growth and oocyte
maturation in women.Conclusions
In conclusion, granulosa-luteal cells from women who
received rLH supplementation during IVF/ICSI display
increased expression of LHR, AR, AMH, and SOX9. AR,
SOX9 and AMH were positively correlated and may
function in the hormonal milieu affecting late dominant
follicles under COH. These markers may be used as a
panel of molecular markers during COH.
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Additional file 1: Figure S1. Quantitative analysis of LHR, AR, AMH,
SOX9 mRNA levels in granulosa-luteal cells collected at oocyte retrieval.
Each bar represents the mean ± SD. Concomitant detection of 18S mRNA
in the real-time RT-PCR reaction served as a reference for relative
quantification. * P < 0.05.
Additional file 2: Figure S2. The effects of rLH and DHT on AR and
AMH expression. (A) AR and (B) AMH expression levels were measured in
HO-23 human granulosa cells under serum-free conditions in the
presence of DHT or rLH at the indicated concentrations for 24 hours.
Data are expressed as the mean +/- standard deviation (SD) of three
different experiments. Concomitant detection of 18S mRNA in the
real-time RT-PCR reaction served as a reference for relative quantification
* P < 0.05 vs. ethanol treatment; DHT, dihydrotestosterone; rLH, luteinizing
hormone.
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